BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28322591)

  • 1. Insight into the structural requirements of pyrimidine-based phosphodiesterase 10A (PDE10A) inhibitors by multiple validated 3D QSAR approaches.
    Halder AK; Amin SA; Jha T; Gayen S
    SAR QSAR Environ Res; 2017 Mar; 28(3):253-273. PubMed ID: 28322591
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors.
    Kulkarni SS; Patel MR; Talele TT
    Bioorg Med Chem; 2008 Apr; 16(7):3675-86. PubMed ID: 18299198
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural findings of cinnolines as anti-schizophrenic PDE10A inhibitors through comparative chemometric modeling.
    Mondal C; Halder AK; Adhikari N; Jha T
    Mol Divers; 2014 Aug; 18(3):655-71. PubMed ID: 24789056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of imidazo[1,5-a]pyrido[3,2-e]pyrazines as a new class of phosphodiesterase 10A inhibitiors.
    Höfgen N; Stange H; Schindler R; Lankau HJ; Grunwald C; Langen B; Egerland U; Tremmel P; Pangalos MN; Marquis KL; Hage T; Harrison BL; Malamas MS; Brandon NJ; Kronbach T
    J Med Chem; 2010 Jun; 53(11):4399-411. PubMed ID: 20450197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined 2D and 3D-QSAR, molecular modelling and docking studies of pyrazolodiazepinones as novel phosphodiesterase 2 inhibitors.
    Bhansali SG; Kulkarni VM
    SAR QSAR Environ Res; 2014; 25(11):905-37. PubMed ID: 25401514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and Optimization of a Series of Pyrimidine-Based Phosphodiesterase 10A (PDE10A) Inhibitors through Fragment Screening, Structure-Based Design, and Parallel Synthesis.
    Shipe WD; Sharik SS; Barrow JC; McGaughey GB; Theberge CR; Uslaner JM; Yan Y; Renger JJ; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2015 Oct; 58(19):7888-94. PubMed ID: 26378882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition mechanism exploration of quinoline derivatives as PDE10A inhibitors by in silico analysis.
    Wu Q; Gao Q; Guo H; Li D; Wang J; Gao W; Han C; Li Y; Yang L
    Mol Biosyst; 2013 Mar; 9(3):386-97. PubMed ID: 23354020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of [¹¹C]MK-8193 as a PET tracer to measure target engagement of phosphodiesterase 10A (PDE10A) inhibitors.
    Cox CD; Hostetler ED; Flores BA; Evelhoch JL; Fan H; Gantert L; Holahan M; Eng W; Joshi A; McGaughey G; Meng X; Purcell M; Raheem IT; Riffel K; Yan Y; Renger JJ; Smith SM; Coleman PJ
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4893-4898. PubMed ID: 26077491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Methylanilide and N-methylbenzamide derivatives as phosphodiesterase 10A (PDE10A) inhibitors.
    Kilburn JP; Kehler J; Langgård M; Erichsen MN; Leth-Petersen S; Larsen M; Christoffersen CT; Nielsen J
    Bioorg Med Chem; 2013 Oct; 21(19):6053-62. PubMed ID: 23978358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of MK-8189, a Highly Potent and Selective PDE10A Inhibitor for the Treatment of Schizophrenia.
    Layton ME; Kern JC; Hartingh TJ; Shipe WD; Raheem I; Kandebo M; Hayes RP; Huszar S; Eddins D; Ma B; Fuerst J; Wollenberg GK; Li J; Fritzen J; McGaughey GB; Uslaner JM; Smith SM; Coleman PJ; Cox CD
    J Med Chem; 2023 Jan; 66(2):1157-1171. PubMed ID: 36624931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of 4-hydroxy-1,6-naphthyridine-3-carbonitrile derivatives as novel PDE10A inhibitors.
    Bauer U; Giordanetto F; Bauer M; O'Mahony G; Johansson KE; Knecht W; Hartleib-Geschwindner J; Carlsson ET; Enroth C
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1944-8. PubMed ID: 22321214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Triazoloquinazolines as a novel class of phosphodiesterase 10A (PDE10A) inhibitors.
    Kehler J; Ritzen A; Langgård M; Petersen SL; Farah MM; Bundgaard C; Christoffersen CT; Nielsen J; Kilburn JP
    Bioorg Med Chem Lett; 2011 Jun; 21(12):3738-42. PubMed ID: 21602043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of highly potent phosphodiesterase 10A (PDE10A) inhibitors: Synthesis and in vitro evaluation of 1,8-dipyridinyl- and 1-pyridinyl-substituted imidazo[1,5-a]quinoxalines.
    Wagner S; Scheunemann M; Dipper K; Egerland U; Hoefgen N; Steinbach J; Brust P
    Eur J Med Chem; 2016 Jan; 107():97-108. PubMed ID: 26562545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the binding properties of T-773 as a PET radioligand for phosphodiesterase 10A.
    Harada A; Suzuki K; Miura S; Hasui T; Kamiguchi N; Ishii T; Taniguchi T; Kuroita T; Takano A; Stepanov V; Halldin C; Kimura H
    Nucl Med Biol; 2015 Feb; 42(2):146-54. PubMed ID: 25451212
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel benzimidazole derivatives as phosphodiesterase 10A (PDE10A) inhibitors with improved metabolic stability.
    Chino A; Masuda N; Amano Y; Honbou K; Mihara T; Yamazaki M; Tomishima M
    Bioorg Med Chem; 2014 Jul; 22(13):3515-26. PubMed ID: 24837154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design and synthesis of a novel 2-oxindole scaffold as a highly potent and brain-penetrant phosphodiesterase 10A inhibitor.
    Yoshikawa M; Kamisaki H; Kunitomo J; Oki H; Kokubo H; Suzuki A; Ikemoto T; Nakashima K; Kamiguchi N; Harada A; Kimura H; Taniguchi T
    Bioorg Med Chem; 2015 Nov; 23(22):7138-49. PubMed ID: 26494583
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple molecular modelling studies on some derivatives and analogues of glutamic acid as matrix metalloproteinase-2 inhibitors.
    Jha T; Adhikari N; Saha A; Amin SA
    SAR QSAR Environ Res; 2018 Jan; 29(1):43-68. PubMed ID: 29254380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AMG 580: a novel small molecule phosphodiesterase 10A (PDE10A) positron emission tomography tracer.
    Chen H; Lester-Zeiner D; Shi J; Miller S; Glaus C; Hu E; Chen N; Able J; Biorn C; Wong J; Ma J; Michelsen K; Hill Della Puppa G; Kazules T; Dou HH; Talreja S; Zhao X; Chen A; Rumfelt S; Kunz RK; Ye H; Thiel OR; Williamson T; Davis C; Porter A; Immke D; Allen JR; Treanor J
    J Pharmacol Exp Ther; 2015 Feb; 352(2):327-37. PubMed ID: 25502803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia.
    Menniti FS; Chappie TA; Humphrey JM; Schmidt CJ
    Curr Opin Investig Drugs; 2007 Jan; 8(1):54-9. PubMed ID: 17263185
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
    Hu E; Kunz RK; Rumfelt S; Andrews KL; Li C; Hitchcock SA; Lindstrom M; Treanor J
    Bioorg Med Chem Lett; 2012 Nov; 22(22):6938-42. PubMed ID: 23044369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.